The Q2 2026 10-Q, filed on August 11, is a financial document whose load-bearing facts are no longer on the income statement. The headline is the Merger Agreement that AtaiBeckley signed with Eli Lilly on July 15, 2026, ten working days after the quarter closed: a $6.75-per-share cash tender, plus one non-tradeable contingent value right per share worth up to $2.50, payable only if VLS-01 enters Phase 3 before the fourth anniversary of close, BPL-003 wins FDA approval and DEA rescheduling inside five years, or VLS-01 wins FDA approval and DEA rescheduling inside seven years. The stock jumped 33% on July 16 from $5.36 to $7.15 and is now at $7.25 against the deal's $6.75 cash component, meaning the public market is pricing roughly $0.50 of expected CVR value - about 20% of the maximum payout - into the spread. Deal value at the cash-only headline is $2.49 billion, or up to $3.42 billion if every CVR milestone is met. A special meeting of stockholders is scheduled for September 8, 2026; closing is targeted for the third quarter.
Underneath the deal, the operating story accelerated. Q2 research and development expense rose 153.1% year over year to $28.1 million from $11.1 million, driven by the start of two BPL-003 Phase 3 studies in treatment-resistant depression (TRD) - ReConnection-1 and ReConnection-2 - and the VLS-01 Elumina Phase 2b readout that management says is on track for the fourth quarter. The 75% headcount expansion from the November 2025 Beckley Psytech combination added $4.5 million to personnel and another $2.6 million to stock-based compensation. Net loss for the quarter widened 17.3% to $32.5 million from $27.7 million, and the H1 2026 operating cash use was $56.4 million. Cash plus short-term securities stood at $191.8 million at June 30, 2026, plus a $34.0 million COMPASS Pathways stake and a $5.9 million Bitcoin position - total liquid resources of $231.7 million, sufficient for the 12-month standalone runway the company asserts in its going-concern language.
The single number the market is wrong about is the CVR. The 20% probability the public is pricing in for the $2.50 per-share CVR aggregate underweights the data the company is on track to produce in the next 12 months. The VLS-01 Phase 3 trigger ($1.00 of the $2.50) is the most credible near-term milestone: Elumina already dosed its last patient in Q2 and the topline is guided for Q4 2026, and a positive readout effectively programs the Phase 3 initiation inside the four-year window. If the public were pricing a 50/50 on VLS-01 Phase 3 initiation alone, the implied per-share value would be $0.50 higher than the $0.50 currently embedded.